Table 3 Univariate and multivariate Cox regression of prognostic variables for overall survival in the cohort

Age

0.250

 < 65

1 (reference)

 ≥ 65

1.130 (0.918–1.392)

Gender

0.638

 Female

1 (reference)

 Male

1.049 (0.859–1.282)

Preoperative CA19-9

0.003

0.002

 < 100U/mL

1 (reference)

1 (reference)

 ≥ 100U/mL

1.367 (1.113–1.678)

1.437 (1.137–1.819)

Preoperative CEA

< 0.001

0.324

 < 5U/mL

1 (reference)

1 (reference)

 ≥ 5U/mL

1.486 (1.198–1.844)

1.191 (0.886–1.366)

Preoperative NLR

< 0.001

0.068

 < 1.80

1 (reference)

1 (reference)

 ≥ 1.80

1.457 (1.170–1.815)

1.257 (0.983–1.607)

Preoperative PLR

0.007

0.581

 < 170.8

1 (reference)

1 (reference)

 ≥ 170.8

1.320 (1.078–1.617)

1.067 (0.848–1.343)

Preoperative FPR

< 0.001

 < 0.001

 < 14.77

1 (reference)

1 (reference)

 ≥ 14.77

1.631 (1.326–2.007)

1.489 (1.196–1.854)

Location

0.834

 Head

1 (reference)

 Body or Tail

0.977 (0.788–1.212)

Tumor differentiation

0.002

0.013

 Well or Moderate

1 (reference)

1 (reference)

 Poor

1.367 (1.122–1.666)

1.290 (1.056–1.577)

pT stage

 T1

1 (reference)

1 (reference)

 T2

1.263 (0.913–1.748)

0.158

1.139 (0.818–1.586)

0.441

 T3

1.451 (1.019–2.067)

0.039

1.291 (0.898–1.855)

0.167

pN stage

0.048

0.188

 N0

1 (reference)

1 (reference)

 N1/N2

1.258 (1.002–1.453)

1.124 (0.931–1.298)

Lymphovascular invasion

0.046

0.224

 No

1 (reference)

1 (reference)

 Yes

1.329 (1.003–1.561)

1.164 (0.911–1.489)

Extrapancreatic invasion

0.044

0.096

 No

1 (reference)

1 (reference)

 Yes

1.232 (1.006–1.509)

1.194 (0.969- 1.472)

Perineural invasion

0.156

 No

1 (reference)

 Yes

1.158 (0.946–1.417)

Resectability status

0.001

0.004

 Resectable

1 (reference)

1 (reference)

 Borderline resectable

1.661 (1.224–2.254)

1.589 (1.157–2.181)

Adjuvant chemotherapy

 No

1 (reference)

1 (reference)

 Gemcitabine-based

0.693 (0.560–0.858)

 < 0.001

0.671 (0.540–0.834)

 < 0.001

 (m)-FOLFIRINOX

0.591 (0.412–0.846)

0.004

0.539 (0.372–0.782)

0.001